Breaking News Instant updates and real-time market news.

2019-12-02 08:39:57 PHAT Phathom Pharmaceuticals $25.80 0.8 (3.20%) , CELG Bought by BMY $0.00 (0.00%) … 08:39 12/02/19 12/02 08:39 12/02/19 08:39	Phathom Pharmaceuticals CEO David Socks moves to CFO, Terrie Curran to succeed Phathom Pharmaceuticals (PHAT) announced multiple executive appointments. Terrie Curran, former president of the global inflammation and immunology franchise at Celgene (CELG), now joins Phathom as CEO. Founding CEO David Socks transitions to interim CFO and remains a member of the board. In addition to Curran, also joining the Phathom leadership team are Eckhard Leifke as CMO, Joseph Hand, as chief administrative officer and Larry Miller as general counsel. Phathom also announced that Asit Parikh has replaced Chris Slavinsky on the company's board. Leifke joins Phathom from Omeros (OMER) where he served as CMO. Hand joins Phathom from Celgene, where he most recently served as executive VP, global human resources and corporate services and a member of its executive committee. Miller joins Phathom as general counsel from Cyclerion Therapeutics where he served as general counsel and secretary. PHAT Phathom Pharmaceuticals $25.80 0.8 (3.20%) CELG Bought by BMY $0.00 (0.00%) OMER Omeros $14.76 0.38 (2.64%)	04 Dec 07 Dec 25 Mar 04 Apr
PHAT CELG OMER PHAT Phathom Pharmaceuticals $25.80 0.8 (3.20%) 11/19/19 EVER 11/19/19 INITIATION EVER Outperform Phathom Pharmaceuticals initiated with an Outperform at Evercore ISI Evercore ISI analyst Umer Raffat initiated coverage of Phathom Pharmaceuticals with an Outperform rating. 11/19/19 11/19/19 INITIATION Fly Intel: Top five analyst initiations Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Shake Shack (SHAK) initiated with a Neutral at Baird. 2. L3Harris Technologies (LHX) initiated with an Overweight at Alembic Global. 3. Phathom Pharmaceuticals (PHAT) was initiated with a Buy at Jefferies and Needham and a Neutral at Goldman Sachs. 4. Cabaletta Bio (CABA) initiated with an Outperform at Cowen and Evercore ISI as well as an Overweight at Morgan Stanley. 5. Agenus (AGEN) resumed with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here. 11/19/19 NEED 11/19/19 INITIATION Target $40 NEED Buy Phathom Pharmaceuticals initiated with a Buy at Needham Needham analyst Alan Carr initiated coverage of Phathom Pharmaceuticals (PHAT) with a Buy rating and $40 price target. The analyst is positive on the company's development of vonoprazan, a "novel oral potassium-competitive acid blocker for the treatment of Erosive Esophagitis and H. pylori infection", noting that its 2015 launch by Takeda (TAK) in Japan has demonstrated benefits over standard of care proton pump inhibitors in both indications. Having licensed the rights from Takeda, the analyst adds that the company's initiated Phase 3 trials in Erosive Esophagitis and H. pylori infection for registration in the U.S., Canada, and Europe, projecting a U.S. launch in 2022 and and U.S. peak sales of $1.9B-$2.0B in 2032. 11/19/19 JEFF 11/19/19 INITIATION Target $32 JEFF Buy Phathom Pharmaceuticals initiated with a Buy at Jefferies Jefferies analyst David Steinberg initiated coverage of Phathom Pharmaceuticals with a Buy rating and $32 price target. He said the company's lead asset, vonoprazan, is "unusually de-risked" after having already achieved commercial success in Japan and he believes the drug could achieve peak sales in the U.S. of over $1B, assuming successful Phase 3 readouts in 2021. CELG Bought by BMY $0.00 (0.00%) 11/01/19 BARD 11/01/19 DOWNGRADE Target $101 BARD Neutral Celgene downgraded to Neutral at Baird As reported previously, Baird analyst Brian Skorney downgraded Celgene to Neutral from Outperform. The analyst cited its recent upward move and doesn't see any reason for holding the shares ahead of ASH where any hair out the TRANSCEND data could put the entire CVR at risk. Skorney maintained his $101 price target on Celgene shares. 11/01/19 BARD 11/01/19 DOWNGRADE Target $101 BARD Neutral Celgene downgraded d to Neutral from Outperform at Baird Baird analyst Brian Skorney downgraded d to Neutral from Outperform with a $101 price target. 09/23/19 GUGG 09/23/19 UPGRADE Target $55 GUGG Buy Agios Pharmaceuticals upgraded to Buy following selloff at Guggenheim Guggenheim analyst Michael Schmidt upgraded Agios Pharmaceuticals (AGIO) to Buy from Neutral following a 20% year-to-date selloff in the shares, stating that the current valuation reflects no value beyond Tibsovo and Idhifa. Even with more conservative estimates, he believes Tibsovo alone is worth $35 per share and Idhifa royalties from Celgene (CELG) are worth $4, giving the stock a one-year "floor valuation" of $39 per share. Meanwhile, feedback from doctors highlights a moderate but "real" commercial opportunity in PKD for Mitapivat, said Schmidt, who set a $55 price target on Agios shares. 11/01/19 STPT 11/01/19 DOWNGRADE STPT Hold Celgene downgraded to Hold from Buy at Standpoint Research Standpoint Research analyst Ronnie Moas downgraded Celgene to Hold from Buy. OMER Omeros $14.76 0.38 (2.64%) 11/05/19 HCWC 11/05/19 NO CHANGE Target $35 HCWC Buy Omeros recent selloff appears unwarranted, says H.C. Wainwright H.C. Wainwright analyst Raghuram Selvaraju believes the recent selloff in shares of Omeros appears unwarranted. Despite the favorable Omidira data, Omeros shares were down over 16% in market trading yesterday, Selvaraju tells investors in a research note. He believes the downside action was driven by "disappointment" that pass-through reimbursement status for Omidira was not formally extended by the Centers for Medicare and Medicaid Services. However, the pullback "appears to have been overdone and premature," says Selvaraju, who reiterates a Buy rating on Omeros with a $35 price target. 05/06/19 CANT 05/06/19 INITIATION CANT Overweight Omeros initiated with an Overweight at Cantor Fitzgerald Cantor Fitzgerald initiated Omeros with an Outperform and $26 price target. 05/06/19 05/06/19 INITIATION Fly Intel: Top five analyst initiations Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. PagerDuty (PD) initiated with an Overweight at Piper Jaffray, with a Neutral at BTIG, with an Outperform at William Blair, with an Overweight at JPMorgan, with a Sector Weight at KeyBanc, with an Equal Weight at Morgan Stanley and with a Sector Perform at RBC Capital. 2. Tufin (TUFN) initiated with a Buy at Jefferies, with an Overweight at Piper Jaffray, with a Market Perform at William Blair, with a Hold at Stifel, with an Outperform at Oppenheimer, with an Overweight at JPMorgan and with an Overweight at Barclay. 3. Aclaris Therapeutics (ACRS) initiated with an Outperform at SVB Leerink. 4. Jumia Technologies (JMIA) initiated with a Neutral at Citi and with a Sector Perform at RBC Capital. 5. Omeros (OMER) initiated with an Overweight at Cantor Fitzgerald. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. 05/06/19 CANT 05/06/19 INITIATION Target $26 CANT Overweight Omeros initiated with an Overweight at Cantor Fitzgerald Cantor Fitzgerald analyst Brandon Folkes initiated coverage of Omeros with an Overweight rating and $26 price target. The analyst believes investors can be rewarded from current levels through the company's pipeline alone. As such, the risk/reward is to the upside, "creating a compelling investment opportunity," Folkes tells investors in a research note.

2019-12-02 08:39:57

PHAT

Phathom Pharmaceuticals

$25.80: 0.8 (3.20%)

, CELG

Bought by BMY

$0.00: (0.00%)

… 08:39

12/02/19

12/02

08:39

12/02/19

08:39

Phathom Pharmaceuticals CEO David Socks moves to CFO, Terrie Curran to succeed

Phathom Pharmaceuticals (PHAT) announced multiple executive appointments. Terrie Curran, former president of the global inflammation and immunology franchise at Celgene (CELG), now joins Phathom as CEO. Founding CEO David Socks transitions to interim CFO and remains a member of the board. In addition to Curran, also joining the Phathom leadership team are Eckhard Leifke as CMO, Joseph Hand, as chief administrative officer and Larry Miller as general counsel. Phathom also announced that Asit Parikh has replaced Chris Slavinsky on the company's board. Leifke joins Phathom from Omeros (OMER) where he served as CMO. Hand joins Phathom from Celgene, where he most recently served as executive VP, global human resources and corporate services and a member of its executive committee. Miller joins Phathom as general counsel from Cyclerion Therapeutics where he served as general counsel and secretary.

PHAT

Phathom Pharmaceuticals

$25.80: 0.8 (3.20%)

CELG

Bought by BMY

$0.00: (0.00%)

OMER

Omeros

$14.76: 0.38 (2.64%)

04
Dec
07
Dec
25
Mar
04
Apr

PHAT
CELG
OMER

PHAT Phathom Pharmaceuticals

$25.80: 0.8 (3.20%)

11/19/19: EVER

11/19/19

11/19/19: NEED

11/19/19: JEFF

CELG Bought by BMY

$0.00: (0.00%)

11/01/19: BARD

11/01/19: BARD

09/23/19: GUGG

11/01/19: STPT

OMER Omeros

$14.76: 0.38 (2.64%)

11/05/19: HCWC

05/06/19: CANT

05/06/19

05/06/19: CANT

TODAY'S FREE FLY STORIES

21:55 12/09/19 12/09 21:55 12/09/19 21:55 General news	Treasury Market Summary » Treasury Market Summary:… Treasury Market Summary: The good news from the November jobs report remained generally supportive for outlook. But with no fresh news, and with a lot of event risk ahead, the bulls were out of steam and equities slumped slightly. Treasury yields were little changed, also finding no new inspiration to move in one direction or another. The calendar was limited to just a $38 B 3-year note auction, which garnered solid support. View the summary.
AUPH Aurinia Pharmaceuticals $15.76 0.31 (2.01%) 21:03 12/09/19 12/09 21:03 12/09/19 21:03 Syndicate	Aurinia Pharmaceuticals 11.1M share Secondary priced at $15.00 » The deal size was… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	10 Dec
GDI Gardner Denver $33.90 -0.19 (-0.56%) 20:08 12/09/19 12/09 20:08 12/09/19 20:08 Downgrade	Gardner Denver rating change at BTIG » Gardner Denver downgraded… Gardner Denver downgraded to Neutral from Buy at BTIG. BTIG analyst Gregory Lewis downgraded Gardner Denver to Neutral from Buy. The analyst cites his expectation of U.S. upstream spending declining about 10% in 2020 amid reduced activity and lower pricing. At WTI oil price in the mid $50's, Lewis contends that oil companies will remain focused on capital discipline and increasing efficiency. The analyst further notes that 2020 should be a "transition year", forecasting "nil orders" for new frac equipment and adding that Gardner Denver will require an uptick in high-margin upstream energy business for the stock to trade higher. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
GDI Gardner Denver $33.90 -0.19 (-0.56%) 19:56 12/09/19 12/09 19:56 12/09/19 19:56 Downgrade	Gardner Denver rating change at BTIG » Gardner Denver downgraded… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
DTCWY Deutsche Wohnen $0.00 (0.00%) 19:50 12/09/19 12/09 19:50 12/09/19 19:50 Downgrade	Deutsche Wohnen rating change at Goldman Sachs » Deutsche Wohnen… Deutsche Wohnen downgraded to Neutral from Buy at Goldman Sachs. Goldman Sachs analyst Jonathan Kownator downgraded Deutsche Wohnen to Neutral from Buy with a EUR 36.3 price target. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

SEGXF Segro $0.00 (0.00%) 19:49 12/09/19 12/09 19:49 12/09/19 19:49 Downgrade	Segro rating change at Goldman Sachs » Segro downgraded to… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
BORR Borr Drilling $6.60 0.46 (7.49%) 19:30 12/09/19 12/09 19:30 12/09/19 19:30 Initiation	Borr Drilling initiated at Goldman Sachs » Borr Drilling initiated… Borr Drilling initiated with a Buy at Goldman Sachs. Goldman Sachs analyst Sahar Islam initiated coverage of Borr Drilling with a Buy rating and NOK 90 price target. The analyst likes offshore exposed oil services and says Borr is exposed to the shallow water jack-up market which is seeing increased utilization as activity picks up. Volume growth should drive the company's EBITDA from $5M in 2019 to $431M in 2022, which will drive the shares "significantly higher," Islam tells investors in a research note. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
INSG Inseego $6.89 -0.05 (-0.72%) 19:26 12/09/19 12/09 19:26 12/09/19 19:26 Syndicate	Breaking Syndicate news story on Inseego » Inseego files to sell… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
FTSV Forty Seven $30.44 16.04 (111.39%) 19:25 12/09/19 12/09 19:25 12/09/19 19:25 Conference/Events	Forty Seven to hold an investor event » Investor Event will be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec 09 Dec
ARQL ArQule $19.71 10.035 (103.77%) 19:25 12/09/19 12/09 19:25 12/09/19 19:25 Conference/Events	ArQule » Management holds an… Management holds an Investor Event to discuss the data presented at the 61st ASH Annual Meeting in Orlando, FL on December 9 at 8 pm. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec 09 Dec 09 Dec 09 Dec

XNCR Xencor $41.41 0.39 (0.95%) 19:25 12/09/19 12/09 19:25 12/09/19 19:25 Conference/Events	Xencor to host analyst & investor meeting » Analyst & Investor… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec 09 Dec
ABR Arbor Realty $14.78 (0.00%) 19:20 12/09/19 12/09 19:20 12/09/19 19:20 Syndicate	Arbor Realty 6.5M share Spot Secondary priced at $14.14 » The deal size was… The deal size was increased from 6.0M shares and priced at low end of $14.14-$14.44 range. JPMorgan, JMP Securities and Raymond James are acting as joint book running managers for the offering. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	10 Dec
STRM Streamline Health $1.25 -0.04 (-3.10%) 18:59 12/09/19 12/09 18:59 12/09/19 18:59 Hot Stocks	Streamline Health delaying Q3 results to resolve amortization charge » Streamline Health… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
NLOK NortonLifeLock $25.43 -0.02 (-0.08%) , INTC Intel $56.52 -0.28 (-0.49%) … 18:55 12/09/19 12/09 18:55 12/09/19 18:55 Periodicals	McAfee weighs combination with NortonLifeLock, WSJ reports » NortonLifeLock (NLOK) has… NortonLifeLock (NLOK) has drawn deal interest from several companies including rival McAfee, which is owned by Intel (INTC), the Wall Street Journal's Cara Lombardo, Corrie Driebusch, and Miriam Gottfried report, citing people familiar with the matter. Among the options being considered, is a combination with the consumer unit of McAfee, the authors say. McAfee has joined Permira and Advent International as possible suitors for NortonLifeLock, which is the new name for Symantec since the company closed a $10.7B pact to sell its enterprise-security business to Broadcom (AVGO) last month, the authors note. Reference Link NLOK NortonLifeLock $25.43 -0.02 (-0.08%) INTC Intel $56.52 -0.28 (-0.49%) AVGO Broadcom $314.49 -1.68 (-0.53%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec 12 Dec 19 Dec 23 Jan
TGTX TG Therapeutics $9.28 2.17 (30.52%) 18:55 12/09/19 12/09 18:55 12/09/19 18:55 Conference/Events	TG Therapeutics to host investor & analyst meeting » Investor & Analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec

NTNX Nutanix $33.87 -0.725 (-2.10%) 18:41 12/09/19 12/09 18:41 12/09/19 18:41 Hot Stocks	Nutanix CEO: We are transitioning to a subscription-based model » In an interview on… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec 13 Dec 16 Dec
SFIX Stitch Fix $25.17 1.04 (4.31%) , MDB MongoDB $131.03 -0.19 (-0.14%) … 18:33 12/09/19 12/09 18:33 12/09/19 18:33 Hot Stocks	Fly Intel: After Hours Movers » UP AFTER EARNINGS: Stitch… UP AFTER EARNINGS: Stitch Fix (SFIX) up 11.6%... MongoDB (MDB) up 8.7%... Phreesia (PHR) up 7.9%... Avid Bioservices (CDMO) up 5.8%... Vail Resorts (MTN) up 3.1%... Toll Brothers (TOL) up 0.9%. ALSO HIGHER: Equillium (EQ) up 18.5% after FDA granted Fast Track designation for itolizumab in treatment of lupus nephritis... Supernus Pharma (SUPN) up 10.2% after update on Phase 3 SPN-810 study in ADHD patients... Agilent (A) up 3.8% after disclosing activist stake taken by Pershing Square... Hepion Pharma (HEPA) up 3.0% after disclosing CRV431 data at HEP DART meeting. DOWN AFTER EARNINGS: Construction Partners (ROAD) down 17.4%... Casey's (CASY) down 5.9%... Chewy (CHWY) down 2.4%. ALSO LOWER: Livongo Health (LVGO) down 4.7% after selling stock for holders. Movers as of 18:15ET. SFIX Stitch Fix $25.17 1.04 (4.31%) MDB MongoDB $131.03 -0.19 (-0.14%) PHR Phreesia $29.01 -0.09 (-0.31%) CDMO Avid Bioservices $5.85 0.05 (0.86%) MTN Vail Resorts $231.30 -1.43 (-0.61%) TOL Toll Brothers $41.40 0.515 (1.26%) EQ Equillium $4.00 -0.03 (-0.74%) SUPN Supernus $22.69 -0.145 (-0.63%) A Agilent $81.68 -0.545 (-0.66%) HEPA Hepion Pharmaceuticals $5.61 0.4 (7.68%) ROAD Construction Partners $20.56 0.66 (3.32%) CASY Casey's General Stores $175.33 -0.47 (-0.27%) CHWY Chewy $24.17 -0.76 (-3.05%) LVGO Livongo Health $27.40 -0.6 (-2.14%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec 09 Dec 09 Dec 09 Dec 09 Dec 09 Dec 10 Dec 10 Dec 10 Dec 10 Dec 11 Dec 12 Dec 18 Dec 19 Dec
BLUE Bluebird Bio $76.72 -2.79 (-3.51%) , BMY Bristol-Myers $61.32 1.38 (2.30%) 18:24 12/09/19 12/09 18:24 12/09/19 18:24 Hot Stocks	Bluebird Bio, Bristol-Myers present update on Phase 1 study of bb21217 » Bluebird bio (BLUE) and… BLUE Bluebird Bio $76.72 -2.79 (-3.51%) BMY Bristol-Myers $61.32 1.38 (2.30%) Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec 11 Dec
BA Boeing $351.25 -2.74 (-0.77%) 18:22 12/09/19 12/09 18:22 12/09/19 18:22 Periodicals	Former Boeing employee Pierson to testify at U.S. House hearing, Reuters says » An ex-Boeing employee who… An ex-Boeing employee who warned of issues with 737 production will testify on Wednesday at a U.S. house hearing on the FAA's review of the grounded 737 MAX aircraft, Reuters' David Shepardson reports. The plane has been grounded since March following two fatal crashes in five months, and federal officials say that the FAA is not expected to approve the jet's return to the skies until January at the earliest, Shepardson says. Former Boeing employee Edward Pierson, who had held the position of senior operations manager in the flight test and evaluation division, will testify before the U.S. House Transportation and Infrastructure Committee, the author says. Reference Link 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	10 Dec
OXY Occidental Petroleum $37.34 -0.07 (-0.19%) 18:21 12/09/19 12/09 18:21 12/09/19 18:21 Hot Stocks	Occidental Petroleum director buys 12.9K shares of common stock » In a regulatory filing,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec

OXY Occidental Petroleum $37.34 -0.07 (-0.19%) 18:14 12/09/19 12/09 18:14 12/09/19 18:14 Hot Stocks	Occidental Petroleum director buys 10K shares of common stock » In a regulatory filing,… In a regulatory filing, Occidental Petroleum disclosed that its director William Klesse bought 10K shares of common stock on December 6th. The total transaction size was $388.2K. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec
EDIT Editas Medicine $30.34 -0.6 (-1.94%) 18:02 12/09/19 12/09 18:02 12/09/19 18:02 Hot Stocks	Editas Medicine announces in vivo proof-of-concept data for EDIT-301 » Editas Medicine announced… Editas Medicine announced in vivo proof-of-concept data supporting the development of EDIT-301 as a potentially best-in-class, durable medicine to treat sickle cell disease and beta-thalassemia. EDIT-301 is the first experimental medicine in development using Cas12a. The company reported these data today at the 61st Annual Meeting and Exposition of the American Society of Hematology in Orlando, Fla. In this study, when EDIT-301 was infused into NBSGW mice, HbF levels in human red blood cells were increased by approximately 50 percentage points above background at 16 weeks post-engraftment with pancellular distribution and no lineage skewing. These elevated HbF levels were observed after editing with Cas12a which created an editing profile that enriched genomic changes that favored high and persistent HbF levels. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
MSB Mesabi Trust $23.93 0.71 (3.06%) , CLF Cleveland-Cliffs $8.52 0.38 (4.67%) 17:56 12/09/19 12/09 17:56 12/09/19 17:56 Hot Stocks	Mesabi Trust initiates arbitration against Northshore Mining, Cleveland-Cliffs » The Trustees of Mesabi… The Trustees of Mesabi Trust (MSB) reported that the Trust has initiated arbitration against Northshore Mining Company and its parent, Cleveland-Cliffs (CLF), the lessee/operator of the leased lands. The arbitration proceeding has been commenced with the American Arbitration Association. The Trust asserts claims concerning the calculation of royalties related to the production, shipment and sale of iron ore, including DR-grade pellets. More particularly, the claims involve the Trust's allegations that the Operator has failed to properly record and calculate royalty amounts during the second and third quarters of 2019. Based on information currently available to the Trust, the Trust seeks an award of damages, along with specific performance and declaratory relief. MSB Mesabi Trust $23.93 0.71 (3.06%) CLF Cleveland-Cliffs $8.52 0.38 (4.67%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
FFBC First Financial Bancorp $24.67 0.12 (0.49%) 17:51 12/09/19 12/09 17:51 12/09/19 17:51 Hot Stocks	First Financial Bancorp chairman Davis sells 25,000 common shares » In a regulatory filing,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
GPRE Green Plains $14.26 -0.49 (-3.32%) 17:47 12/09/19 12/09 17:47 12/09/19 17:47 Hot Stocks	Green Plains CEO Todd Becker sold over 607K in company shares » Green Plains CEO Todd… Green Plains CEO Todd Becker disclosed in a filing that he had sold 41,957 shares of company stock at an average price of $14.48 per share on December 5. The total transaction value of the sale was $607,328. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Events

Earnings calls, analyst events, roadshows and more

NUAN
Today at 07:30

Nuance Communications Inc. Firm Sponsored Meetings

Nasdaq MarketSite , New York City, NY
Today at 08:00

Cardiovascular and Renal Drugs Advisory Committee Meeting Government Event

FDA White Oak Campus--10903 New Hampshire Ave--Bldg 31--Great Room 1503, Silver Spring, MD
LITB
Today at 08:00

LightInTheBox - LITB Conference Calls
HDS
Today at 08:00

HD Supply - HDS Conference Calls
DESP
Today at 08:00

Despegar.com, Corp. Firm Sponsored Meetings

, New York, NY
ENB
Today at 08:00

Enbridge Inc Firm Sponsored Meetings

, New York, NY
DBI
Today at 08:30

Designer Brands - DBI Conference Calls
PHR
Today at 08:30

Phreesia - PHR Conference Calls
CMD
Today at 08:30

Cantel Medical - CMD Conference Calls
FRAN
Today at 08:30

Francesca's - FRAN Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	AUPH X AUPH Aurinia Pharmaceuticals Secondary Managers: Jefferies & SVB Leerink, H.C. Wainwright, Oppenheimer, Bloom Burton Priced at: $15.00 11.1M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ABR X ABR Arbor Realty Spot Secondary Managers: JPMorgan, JMP Securities & Raymond James Priced at: $14.14 6.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	CRWD X CRWD Crowdstrike Block Trade Managers: Goldman Sachs $50.89 2.2M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RHP X RHP Ryman Hospitality Spot Secondary Managers: BofA/Merrill, JPMorgan & Wells Fargo $85.60-88.10 3M Shares
Tues	XP X XP XP IPO Managers: Goldman Sachs, JPMorgan, Morgan Stanley, XP & Itau BBA, BofA/Merrill, Citi, Credit Suisse, UBS $22.00-25.00 72.511M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CNST X CNST Constellation Pharmaceuticals Spot Secondary Managers: JPMorgan, Jefferies & Cowen, RBC Capital, SunTrust $36.14 4.75M Shares
Wed	BILL X BILL Bill.com IPO Managers: Goldman Sachs, BofA/Merrill, Jefferies & KeyBanc, Canaccord, Needham, William Blair $16.00-18.00 8.824M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EH X EH Ehang IPO Managers: Morgan Stanley, Needham, Tigress Financial, Prime Number $12.50-14.50 3.2M Shares LVGO X LVGO Livongo Health Secondary Managers: Morgan Stanley, Goldman Sachs & JPMorgan $27.43 2.78M Shares MNRL X MNRL Brigham Minerals Secondary Managers: Credit Suisse, Goldman Sachs & RBC Capital $19.70 11M Shares
Thurs	OCFT X OCFT OneConnect IPO Managers: Morgan Stanley, Goldman Sachs, JPMorgan & Ping An of China, BofA/Merrill, HSBC, CLSA, KeyBanc $12.00-14.00 36M Shares SPT X SPT Sprout Social IPO Managers: Goldman Sachs, Morgan Stanley, KeyBanc & William Blair, Canaccord, Stifel $16.00-18.00 8.824M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

View All Syndicate Announcements »

Phathom Pharmaceuticals CEO David Socks moves to CFO, Terrie Curran to succeed

TODAY'S FREE FLY STORIES

Get Full Fly Access